Get the Stockscreener App
1.315
11.15%
-0.165
After Hours:
1.32
0.005
+0.38%
Atai Life Sciences N V stock is traded at $1.315, with a volume of 1.74M.
It is down -11.15% in the last 24 hours and down -12.33% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$1.48
Open:
$1.365
24h Volume:
1.74M
Relative Volume:
0.64
Market Cap:
$270.69M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-4.6964
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
-16.24%
1M Performance:
-12.33%
6M Performance:
+24.06%
1Y Performance:
-44.98%
1-Day Range:
$1.31
$1.41
1-Week Range:
$1.22
$1.57
52-Week Range:
$1.03
$2.85
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
WALLSTRASSE 16, BERLIN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.315 | 270.69M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com Australia
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa
Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India
Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India
Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India
Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India
Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK
Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews
ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance
Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
How is ATAI’s stock performing after recent trades? - US Post News
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance UK
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com
atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK
Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Atai Life Sciences Prices $55 Million Stock Offering -February 13, 2025 at 04:47 am EST - Marketscreener.com
ATAI Life Sciences Secures Massive $55M War Chest for Breakthrough Mental Health Treatments - StockTitan
atai Life Sciences Announces Pricing of Public Offering of Common Shares - Yahoo Finance
atai Life Sciences unveils $55M public offering to advance mental health treatments - Proactive Investors USA
atai Life Sciences Secures Major Funding: $55M Share Offering to Revolutionize Mental Health Treatment Pipeline - StockTitan
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback (ATAI:NASDAQ) - Seeking Alpha
Evaluating ATAI’s financial ratios for a profitable investment - US Post News
Get in on ATAI Life Sciences N.V’s (ATAI) buy-in window today! - SETE News
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trialICYMI - Proactive Investors USA
ATAI Life Sciences N.V (NASDAQ: ATAI) Has Succeeded In Attracting Investors This Year, The Stock Is Up 59.40% Year-To-Date – Marketing Sentinel - Marketing Sentinel
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe - Proactive Investors USA
ATAI’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):